First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s. | May 4, 2023
PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month period ended March 31, 2023, included herein, have been prepared in. | May 4, 2023
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter.